LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income (loss) | $52,154 | $(33,361) | $57,138 |
| Unrealized net gain (loss) on available-for-sale securities, net of tax | 167 | (67) | (116) |
| Comprehensive income (loss) | $52,321 | $(33,428) | $57,022 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.